Everpar Advisors LLC Buys New Stake in Novo Nordisk A/S (NYSE:NVO)

Everpar Advisors LLC purchased a new position in shares of Novo Nordisk A/S (NYSE:NVO) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 6,127 shares of the company’s stock, valued at approximately $634,000.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Westside Investment Management Inc. grew its stake in shares of Novo Nordisk A/S by 83.3% during the third quarter. Westside Investment Management Inc. now owns 1,428 shares of the company’s stock worth $130,000 after acquiring an additional 649 shares during the last quarter. Kranot Hishtalmut Le Morim Tichoniim Havera Menahelet LTD acquired a new position in Novo Nordisk A/S during the 3rd quarter valued at approximately $2,408,000. Lazard Asset Management LLC lifted its stake in shares of Novo Nordisk A/S by 182.2% during the third quarter. Lazard Asset Management LLC now owns 1,494,214 shares of the company’s stock worth $135,883,000 after buying an additional 964,640 shares during the period. CENTRAL TRUST Co grew its holdings in shares of Novo Nordisk A/S by 111.6% during the third quarter. CENTRAL TRUST Co now owns 6,004 shares of the company’s stock valued at $546,000 after buying an additional 3,166 shares during the last quarter. Finally, Ieq Capital LLC raised its stake in Novo Nordisk A/S by 136.6% in the 3rd quarter. Ieq Capital LLC now owns 27,474 shares of the company’s stock worth $2,498,000 after acquiring an additional 15,860 shares during the last quarter. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Price Performance

Shares of NVO stock traded up $2.69 during mid-day trading on Tuesday, hitting $127.28. 4,166,287 shares of the stock were exchanged, compared to its average volume of 4,840,792. The company has a quick ratio of 0.50, a current ratio of 0.70 and a debt-to-equity ratio of 0.17. Novo Nordisk A/S has a 52-week low of $75.56 and a 52-week high of $138.28. The firm has a fifty day moving average of $127.33 and a 200 day moving average of $113.50. The company has a market cap of $571.17 billion, a PE ratio of 43.89, a price-to-earnings-growth ratio of 1.93 and a beta of 0.43.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on NVO shares. Morgan Stanley assumed coverage on Novo Nordisk A/S in a report on Tuesday, January 23rd. They set an “overweight” rating and a $120.00 target price for the company. Cantor Fitzgerald reissued an “overweight” rating and set a $160.00 target price on shares of Novo Nordisk A/S in a report on Thursday, April 18th. UBS Group assumed coverage on Novo Nordisk A/S in a research report on Tuesday, January 16th. They set a “neutral” rating on the stock. Finally, BMO Capital Markets assumed coverage on Novo Nordisk A/S in a report on Friday, April 12th. They issued an “outperform” rating and a $163.00 price objective for the company. Two analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Novo Nordisk A/S has a consensus rating of “Moderate Buy” and a consensus target price of $133.60.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.